Singulair and phone call

I visited (accidentally) this web site a little over a year ago...it was a total blessing and, I feel, a life saver!!! Our grandson Trevor was totally out of control and talking about killing people and himself at the age of 4 yrs old.
One phone call away from calling a therapist, I saw this and we took him off the Singulair immediately. He has been 1000 times better and not depressed anymore. This is a totally true story and I'm so glad to spread the word. T***'s Grandma

I am a grandma to a 41/2 year old boy named Trevor. He has been on Singulair since he was 18mos. old. I am here to tell I am furious and heartsick to think that he has been subjected to a medication that can do the things it has done to him. I have NO DOUBT that Singulair is the problem. Our daughter and son-in-law have been at their wits end with
him and was one phone call away from taking him to a therapist (they needed one too!) The phone call to me on Monday, July 28th, was out of
sheer desperation. My daughter wanted me to look up the side effects for Zirtec. After looking that up and not finding anything I happened to remember that Trevor was also on Singulair. The actual side effects listed
didn't ring any warning bells with me. Somehow I happened onto this website and OH MY GOSH I flipped out and cried through every letter written by parents with the same side effects Trevor has. The compulsion, anxiety, anger and (heaven forbid) the threats of wanting himself, or someone he loves very much to die.This is absolutely unheard of for someone his age. I'm ever so thankful I found this website. Trevor was taken off Singulair that very day and within 3 days we had the sweetest,
most normal 4yr. old, on this earth. When I think what could have happened
had he stayed on it any longer...I can't!!!

Singulair associated with Churg-Strauss. A study in France and Germany.

Thorax. 2008 Aug;63(8):677-82. Epub 2008 Feb 14. Links
The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study.Hauser T, Mahr A, Metzler C, Coste J, Sommerstein R, Gross WL, Guillevin L, Hellmich B.
Dr A Mahr, Department of Internal Medicine, Hôpital Cochin, 27 rue du Faubourg Saint-Jacques, 75679 Paris Cedex 14, France. alfred.mahr@cch.aphp.fr.

BACKGROUND: There has been some concern that leucotriene receptor antagonists might precipitate the onset of Churg-Strauss syndrome (CSS). A study was undertaken to investigate the relationship between the leucotriene receptor antagonist montelukast and the onset of CSS. METHODS: Medication histories of 78 patients with CSS from France and Germany were retraced by questioning the patients, treating physicians and dispensing pharmacists, and from medical records. Using a case-crossover research design, exposures to montelukast and other asthma medications during the 3-month "index" period immediately preceding the onset of CSS were compared with those of four previous 3-month "control" periods. Odds ratios (ORs) were computed by conditional logistic regression. RESULTS: The ORs for CSS onset were 4.5 (95% CI 1.5 to 13.9) for montelukast, 3.0 (95% CI 0.8 to 10.5) for inhaled long-acting beta(2) agonists, 1.7 (95% CI 0.5 to 5.4) for inhaled corticosteroids and 4.0 (95% CI 1.3 to 12.5) for oral corticosteroids. Montelukast exposure during control periods increased temporally over three consecutive calendar periods of CSS onset from 1999 to 2003 (p(trend) <0.0001). CONCLUSION: Montelukast use was associated with a 4.5-fold higher risk of CSS onset within 3 months. However, the positive estimates obtained for other long-term asthma control medications suggest that this link might be confounded by a general escalation of asthma therapy before CSS onset. The association between montelukast and CSS observed in this study is probably also explained by the increasing use of this medication over time.

PMID: 18276721